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Abstract
The coronavirus disease (COVID-19) has become a global pandemic with a high mortality rate. There has been 
emerging evidence regarding the presence of thrombosis in patients with severe COVID-19 infection. In addition, 
prognosis of COVID patients, once they are complicated with DVT or fatal pulmonary emboli, will also significantly 
decline. Hence, understanding the pathomechanism and prompt treatment of thromboembolism is important in 
improving the outcome in COVID-19 patients. Prophylaxis anticoagulant was proposed for all hospitalized COVID-
19 patients. The aim of this article is to review the current literature regarding pathomechanism, risk assessment, 
diagnosis, and management of VTE.
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Introduction
The coronavirus disease (COVID-19) has 
become a global pandemic. Since December 2019, the 
total number worldwide of confirmed cases is 2,356,414 
with mortality rate 6.8% involving 213 countries all 
over the world (WHO data April 21, 2020) [1]. The first 
two COVID-19 patients in Indonesia were reported on 
March 2, 2020. As per April 21, 2020, the total cases of 
COVID-19 reached 6760 positive cases, of which 590 
had died. The mortality rate in Indonesia was as much as 
8.7%, and it was the highest rate in Southeast Asia [2].
Study of epidemiology and clinical characteristics 
of COVID-19 patients have started to unfold. On the 
other hand, the mortality risk factors and the exact 
clinical course of disease, including shedding of the 
coronavirus, have not been well described. The clinical 
spectrum of COVID-19 ranges from mild to critically ill 
cases. The clinical spectrum of COVID-19 consists of 
mild to critical illness. The previous studies revealed that 
old age, increased SOFA scores, greater d-dimers level 
more than 1000 ng/mL, and those who have pre-existing 
comorbidities are more likely to have a poor prognosis 
[3], [4]. Patient with COVID-19 who fell into severe or 
critical condition is exposed to venous thromboembolism 
potential risk factors such as infection, immobilization, 
respiratory failure, hypoxia, mechanical ventilation, and 
use of central venous catheter (CVC) [5].
Three cases in China showed antiphospholipid 
autoimmune response in patients with COVID-19. 
These findings give rise to coagulopathy roles in 
extensive thromboembolism in patients with COVID-
19 [6]. The prognosis of COVID patients, once they are 
complicated with DVT or fatal pulmonary emboli, will 
significantly decline [5], [7], [8].
This article was aimed to summarize the 
current literature of mechanism and recommendation in 
thromboembolism related COVID-19 patients.
Epidemiology
Venous thromboembolic events (VTE) 
discussed in this article include deep vein thrombosis 
(DVT) and pulmonary embolism (PE). Epidemiology 
data regarding these events in COVID-19 were still very 
limited. The prevalence of VTE, particularly in critically 
ill/severe patients suffering from COVID-19, was 
reported as much as 25–27%. A study from three Dutch 
hospitals showed a 27% incidence of VTE, including 
PE and DVT [5]. Another data from China hospital 
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revealed 25% (25/81) patients with severe COVID-19 
pneumonia developed lower extremity venous 
thrombosis [8]. In a study by Xie et al. in Tongji Hospitals, 
40% (10/25) COVID-19 pneumonia confirmed patients 
who underwent computed tomography pulmonary 
angiography scans (CTPA) were found to be acute PE 
positive [9].
Pathomechanism
COVID-19 may put the patient susceptible 
to both arterial and venous thromboembolism due to 
hypoxia, immobilization, disseminated intravascular 
coagulation (DIC), and excessive inflammation [5]. 
Systemic pro-inflammatory cytokine responses, 
including interleukin-1 and interleukin-6, are mediators 
of atherosclerosis, directly contributing to plaque rupture 
through local inflammation and hemodynamic changes. 
These responses also induce procoagulant factors, 
which predispose to ischemia and thrombosis [4]. 
Patient with COVID-19 who fell into severe or critical 
condition is also exposed to other potential risk factors 
for VTE such as mechanical ventilation, respiratory 
failure, and use of CVC [5].
Cell entry is an important component for 
cross-species transmission, particularly for beta-
coronavirus. Spikes, surface glycoproteins encoded 
by all coronaviruses which bind to host cell receptors, 
mediate the entry of viruses. For beta-coronaviruses, 
the receptor-binding domain, a single region of spike 
protein, mediates interactions with receptors of host 
cell. After binding to the receptor, protease of the 
adjacent host cuts the spike, which liberates fusion 
peptides in spike, facilitating the entry of the virus. 
Familiar host receptors for beta-coronavirus include 
dipeptidyl peptidase-4 for MERS-CoV and angiotensin-
converting enzyme 2 (ACE2) for SARS-CoV. In addition, 
ACE2, which is also the receptor for SARS-CoV-2, is 
expressed on myocytes and vascular endothelial cells. 
The dysfunction of vascular endothelial cells is one of 
the mechanisms of thrombus formation [10].
Endothelial cell dysfunction caused by infection 
results in excess thrombin production and cessation of 
fibrinolysis, which indicates a state of hypercoagulability 
in patients with infections such as COVID-19. In 
addition, hypoxia found in severe COVID-19 can induce 
thrombosis by increasing not only viscosity of blood but 
also signaling pathways that depend on transcription 
factors induced by hypoxia [11].
Study by Chen et al. revealed index of 
biochemical examination of 99 patients with COVID-19 
pneumonia, and also reported an abnormal biochemical 
indexes phenomenon related to patients’ hemoglobin. 
This report shows that the number of neutrophils and 
hemoglobin in most patients decreased, while the rate 
of erythrocyte sedimentation, serum ferritin, albumin, 
C-reactive protein, and lactate dehydrogenase in many 
patients increased significantly [12].
Whenzong and Hualan hypothesize a possible 
involvement of hemoglobin in the pathogenesis of 
COVID-19 [13]. When hemoglobin decreases, and 
heme increases, the body will accumulate too much 
dangerous iron ions, which will induce inflammation 
and increase albumin and C-reactive protein. Cells 
react to stress due to inflammation, creating large 
amounts of serum ferritin to bind to free iron to reduce 
destruction [13]. The previous study stated that iron 
ion might cause endothelial dysfunction, including 
vascular endothelial. A study by Zhu concludes 
that intravascular nanoparticles of iron oxide may 
provoke inflammation and dysfunction of endothelial 
cells [14]. However, that proposed pathogenesis of 
hemoglobin in COVID-19 by Whenzong and Hualan 
has received critical commentary by Read et al. due 
to the lack of experimental evidence to support any of 
their conclusions and their claiming the therapeutic 
effect of drugs that are only just entering clinical 
trials [15].
The presence of antiphospholipid (aPL) 
antibodies might also eventually cause thrombosis. 
Anticardiolipin IgA antibodies, as well as anti-
β2-glycoprotein I IgA and IgG antibodies, were 
found in COVID-19 patients [6]. Antiphospholipid 
antibodies target phospholipid protein abnormally, 
and the presence of these antibodies is important 
in antiphospholipid syndrome diagnosis. Still, these 
antibodies can also increase temporarily in patients 
with critical diseases and various infections. In 
critical patients such as thrombotic microangiopathy, 
heparin-induced thrombocytopenia, and disseminated 
intravascular coagulation, the appearance of these 
antibodies may rarely cause thrombotic events that are 
difficult to distinguish from other causes of multifocal 
thrombosis [6]. The main antigenic target of the aPL 
antibody is known as β2-glycoprotein I (β2GPI), 
mediating the binding of aPL antibodies to target cells, 
including monocyte, endothelial cells, trophoblast, 
and platelet, which lead to pro-inflammatory and 
prothrombotic changes that subsequently result in 
thrombosis [16].
The net results of those mechanisms may induce 
the development of subclinical thrombosis in patients 
suffering from COVID-19. Increased D-dimer, a sign of 
excessive coagulation activation and hyperfibrinolysis, 
may explain the result of those pathomechanisms. 
D-dimer is often used to identify active thrombus with high 
sensitivity but low specificity. Patients with COVID-19 
have an increase of the D-dimer level. After undergoing 
therapeutic anticoagulation, D-dimer level decreases 
continuously, which means D-dimer can predict not 
only thrombosis but also monitor anticoagulant’s 
effectiveness [7]. Another evidence, histopathology 
study on lung biopsy of critical patients with COVID-19, 
revealed the presence of occlusion and microthrombosis 
formation in pulmonary small vessels [17].
T1 - Thematic Issue “Coronavirus Disease (COVID-19)” Cardiology
68 https://www.id-press.eu/mjms/index
Risk assessment and diagnosis
It is important to identify which patients with 
COVID-19 are at increased risk of VTE. Current clinical 
recommendation state that thromboprophylaxis should 
be given to all acute patient with high risk of VTE. 
Modified IMPROVE-VTE risk score is a scoring system 
that combines D-Dimer level with other VTE clinical 
predictors to identify patients with high-risk VTE who are 
eligible for thromboprophylaxis medication (Table 1). 
Marker for higher VTE risk is a total score of 4 or 2–3 
with D-dimer level at the time of screening is more than 
twice the upper limit of normal range [18].
Table 1: Modified IMPROVE VTE risk score
VTE risk factor VTE risk score
Previous VTE 3
Known thrombophiliaa 2
Current lower limb paralysis or paresisb 2
History of cancerc 2
ICU/CCU stay 1
Complete immobilizationd ≥ 1 day 1
Age ≥ 60 years 1
CCU: Cardiac care unit, ICU: Intensive care unit, IMPROVE: International Medical Prevention Registry 
on Venous Thromboembolism, NIH: National Institutes of Health, VTE: Venous thromboembolism. aA 
congenital or acquired condition that causes the risk of excessive thrombosis (e.g., factor C or S deficiency, 
lupus anticoagulant, Leiden Factor V). bFeet falls into bed 5 s but has an effort against gravity (taken from 
the NIH stroke scale). cCancer (not including non-melanoma skin cancer) at any time in the past 5 years 
(cancer must be in remission to meet eligibility criteria). dImmobilization is limited to beds or chairs with or 
without bathroom privileges.
Risk of pulmonary embolism
The clinical manifestation of acute PE is not 
specific. Symptoms include chest pain, dyspnea, 
hemoptysis, and syncope. COVID-19 may exhibit 
symptoms that bear a misleading resemblance to 
acute PE. This generates a diagnostic challenge for 
clinician treating patient with COVID-19. Identifying 
the presence of risk factors of VTE is vital to determine 
disease clinical probability. Revised Geneva Rule and 
Wells Score are often used as prediction rules. They 
combine symptoms, clinical findings, and risk factors 
to classify patients with suspected PE into specific 
category, separating them from the others. Acute 
thrombosis will activate coagulation and fibrinolysis, 
leading to increase serum D-dimer. D-dimer has high 
negative predictive value in diagnosing acute PE. If 
D-dimer level is normal, then the diagnosis of acute 
PE is unlikely. Meanwhile, the positive predictive value 
of high D-dimer is low. Making it less meaningful to 
confirm the presence of acute PE [19].
Several studies reported that increased 
D-dimer levels (>1000 ng/mL) are a potential predictor 
for mortality. D-dimer level has low specificity value, 
making it unfavorable as a screening tool. Relying 
D-Dimer as screening tool might cause overutilization 
of CTPA if applied in patients with acute kidney 
injury [20].
Prompt diagnosis of PE for patient presenting 
with respiratory distress, desaturation, and hypotension 
is crucial to improve the clinical outcomes. Despite 
the lack of evidence, assessment of serial D-dimer 
alongside imaging modalities such as bedside 
echocardiography or Doppler ultrasound will provide 
valuable information to determine the presence of PE 
in patients with COVID-19 infection [21]. A recent study 
examining 25 patients suspected of PE showed that 
D-dimer levels in patients with confirmed PE had values 
higher than 7000 ng/mL, significantly higher than those 
without PE [9], [21].
Risk of deep vein thrombosis
The initial step in the diagnostic algorithm of 
DVT suspicion is using two levels modified wells score. It 
will classify DVT suspected patients into two categories 
(DVT unlikely or likely). For DVT-unlikely, D-dimer 
examination is established. Normal D-dimer renders DVT 
unlikely. In patients with DVT-likely, D-Dimer testing is not 
required, but imaging is required. If not contraindicated, 
anticoagulation therapy must be started in patients with 
DVT-likely until imaging. First-line imaging modality of 
DVT is venous ultrasonography [22].
Elevated serum D-dimer level
Study by Cui, et al. revealed that one-fourth 
of COVID-19 patients developed VTE. VTE was 
strongly correlated with elevated serum D-dimer level, 
as shown in Table 2. The authors subsequently tested 
several D-dimer cutoff value to predict VTE occurrence 
(Table 3). The best cutoff of D-Dimer value was 1500 ng/
ml (85% sensitivity and 89% specificity). This supports 
the concept of empiric anticoagulation for patients with 
markedly elevated D-dimers (particularly in situations 
where frequent CT angiography and Doppler Ultrasound 
is impossible due to logistic restraints) [8].
Table 2: Characteristics between the VTE and non-VTE groups 
(n = 81)
Characteristics Normal range VTE (n = 20) Non-VTE (n = 61) p-value
Age (years) - 68.4 ± 9.1 57.1 ± 14.3 0.001
Leukocytes (×109/L) 3.5–9.5 7.8 ± 3.1 6.6 ± 2.6 0.120
Lymphocytes (×109/L) 1.1–3.2 0.8 ± 0.4 1.3 ± 0.6 <0.001
Platelets (×109/L) 125.0–350.0 246.6 ± 110.6 248.8 ± 111.7 0.938
Hemoglobin (g/L) 115.0–150.0 123.2 ± 16.5 125.3 ± 16.7 0.633
APTT (s) 27.0–45.0 39.9 ± 6.4 35.6 ± 4.5 0.001
Prothrombin time (s) 11.0–16.0 15.4 ± 1.0 15.6 ± 1.0 0.465
D-dimer (ug/mL) 0.0–0.5 5.2 ± 3.0 0.8 ± 1.2 <0.001
Due to current limited studies, initiating full dose 
of anticoagulation based on D-dimer value will remain 
controversial. For now, these decisions may be judged 
on a patient-by-patient basis, considering both risks of 
thrombosis and hemorrhage. Among patients without 
risk factors for hemorrhage, empiric anticoagulation 
may be reasonable for patients with D-dimer levels 
above ~1500 ng/ml [8].
Table 3: Sensitivity, specificity, positive predictive value, and 
negative predictive value of different D-dimer cutoff levels for 
predicting VTE in COVID-19 patients
Cutoff (μg/mL) Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1.0 85.0 77.0 54.8 94.0
1.5 85.0 88.5 70.8 94.7
2.0 80.0 90.2 72.7 93.2
2.5 70.0 93.4 77.8 90.5
3.0 70.0 96.7 87.5 90.8
3.5 65.0 96.7 86.7 89.4
PPV: Positive predictive value, NPV: Negative predictive value
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In conclusion, modified IMPROVE-VTE risk 
score and serum D-Dimer level are valuable tools to 
help identify COVID-19 patients at increased risk of 
VTE. Increased D-Dimer level above 1500 ng/ml has 
the best sensitivity and specificity value for predicting 
the VTE events in COVID-19 patients. The diagnosis of 
PE and DVT require imaging modality such as bedside 
echocardiography or Doppler ultrasound.
Management
Anticoagulant
Most patients with COVID-19 may have 
excessive activation of coagulation and will 
consequently have microthrombi [17]. Hence, several 
interim guidelines and health-care center protocols 
agreed that all hospitalized COVID-19 patients must 
all be in some form of anticoagulation, whether it is 
confirmed VTE or not [23], [24], [25], [26], [27].
Heparin, including LMWH or its synthetic 
form, is commonly used as an anticoagulant to 
prevent DIC and VTE in patients with infection 
due to its anti-inflammatory effects. As well as 
preventing thrombosis, heparin has its property to 
lower cytokine levels and prevents cytokine storm 
in patients with COVID-19 [23], [28], [29]. American 
Society of Hematology (ASH) recommends LMWH or 
Fondaparinux over UFH for all hospitalized patients 
unless increased bleeding risk is present. While in 
patients with heparin-induced thrombocytopenia 
history, it is recommended to use fondaparinux. If 
anticoagulants are not available or contraindicated, 
then mechanical thromboprophylaxis is advised (e.g., 
pneumatic compression device) [24], [30].
A retrospective analysis by Tang et al. comparing 
28-day mortality between heparin users and non-users 
of 449 consecutive patients with severe COVID-19 
was done in China. Ninety-nine patients had received 
heparin for 7 days or longer. They found no significant 
difference in 28-day mortality between heparin users 
and non-users (30.3% vs. 29.7% p = 0.910). However, 
in patients with sepsis-induced coagulopathy (SIC) 
score ≥4 (Table 4), mortality was significantly reduced 
by anticoagulant medication (p = 0.029). In patients 
with D-dimers >3000 ng/mL (6 times of the normal 
upper limit), anticoagulation results in a 20% mortality 
reduction (p = 0.017) [11].
Table 4: ISTH SIC scoring system [11]
Item Score Range
Platelet count (×109/L) 1 100–150
2 <100
PT-INR 1 1.2–1.4
2 >1.4
SOFA score 1 1
2 ≥2
Total score for SIC 4
INR: International normalized ratio, ISTH: The International Society on Thrombosis and Hemostasis, 
SIC: Sepsis-induced coagulopathy, SOFA: Sequential organ failure assessment
The International Society of Thrombosis 
and Hemostasis (ISTH)
The interim guidance delivers risk stratification 
of coagulopathy at admission for patients with COVID-19 
and coagulopathy management (Figure 1) [23]. Their 
recommendations including:
1. Patients with high D-dimers (e.g., arbitrarily 
defined as 3–4 times increase) will need to be 
hospitalized.
2. Monitoring the reduction in fibrinogen levels 
later in the course of the disease (e.g., days 
10–14) can help in determining whether the 
patient has progressed to DIC.
3. LMWH should be considered in all patients 
(including those who are not critical) who need 
to be hospitalized for COVID-19, if there are no 
contraindications:
•	 Active hemorrhage
•	 Platelet count <25 × 109/L
•	 Monitoring recommended for severe renal 
impairment
•	 Abnormal PT or aPTT is not a contraindication
4. LMWH might carry anti-inflammatory properties 
that provide added benefits in COVID-19 
infection.
Prophylactic anticoagulant
Brigham and Women’s Hospital guideline 
recommendation of standard prophylactic 
anticoagulation for thrombotic disease management in 
all hospitalized COVID-19 is as follows [27]:
1. If GFR >30 mL/min: Enoxaparin 40 mg 
subcutaneous (SC) daily
2. If GFR <30 mL/min or acute kidney injury: 
Unfractionated heparin (UFH) 5000 units SC q8hr
3. Hold if platelets <30,000 or bleeding, start 
thromboembolic deterrent stockings, and 
sequential compression devices.
Klok et al. reported that in spite of prophylaxis 
anticoagulant administration, 27% of patients had later 
developed VTE, and 4% had an incidence of arterial 
thromboembolism (which may be underestimated, due 
to the lack of systematic screening for this event and the 
interrupted observation period in some patients). As a 
result, they recommend doubling the conventional dose 
of heparin prophylaxis (e.g., Enoxaparin 40 mg twice a 
day, rather than once a day) [5]. Prophylactic doses higher 
than standard doses can also be considered in patients 
with elevated D-dimers (e.g., 500–1500 ng/mL) [31]:
GFR > 30 mL/min: Enoxaparin 0.5 mg/kg 
q12hr. Check anti-Xa level 4 h after the third dose, with 
a target level of 0.5–0.8 IU/ml.
1. GFR < 30 mL/min: UFH 7500 units q8hr 
(consider dose adjustment for atypical weight 
patients).
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Therapeutic anticoagulant
Therapeutic anticoagulation with heparin has 
been proposed for patients with D-dimers level greater 
than 2000 ng/ml, but this has not been proven [11], [32]. 
At present, therapeutic anticoagulation was limited to 
COVID-19 patients with documented acute VTE, and pre-
hospital management with therapeutic anticoagulation 
(such as for recurrent VTE, certain mechanical heart valves, 
and atrial fibrillation). In general, the recommendation for 
VTE therapeutic as follows [23], [25], [26, [27], [33]:
1. If the patient uses direct oral anticoagulant 
(DOAC) or warfarin for Afib or VTE, switch 
to the full dose of anticoagulant (LMWH 
or UFH, according to indications based on 
kidney function or clinical conditions; LMWH is 
preferred over UFH to reduce blood drawing 
in monitoring PTT because of more possible 
interactions with COVID 19).
2. If the patient has confirmed acute PE or DVT or is 
undergoing anticoagulant therapy before being 
hospitalized and is now converted to parenteral, 
the following guidelines are recommended:
a. LMWH is preferred to minimize blood 
drawing and has superior efficacy in critical 
care population [26].
b. Patients who need to use UFH (not LMWH) 
should be monitored with anti-Xa levels (in 
contrast to PTT given that the increases in 
COVID-19 patients who are severe and can 
make PTT unreliable) [26].
3. Consult with a hematologist to discuss specific 
guidelines if coagulopathy in the patient 
appears to be deteriorating or to discuss an 
escalated or modified treatment approach, 
as some hematologic disorder such as 
thrombocytopenia increased risk of severity 
and mortality in COVID-19 [34].
4. Farkas proposed a possible approach to 
empiric anticoagulation with a limit of D-dimer 
above 1000–2000 ng/ml, fibrinogen level, 
thromboelastography (TEG) as guidance, as 
shown in Figure 2. This author states that 
this approach has not yet been supported 
by any high-level evidence, and the decision 
to provide anticoagulants should preferably 
be individualized, so this is only intended 
as an approach scheme in the management 
of patients. In the case of very advanced 
stages, severe disease may be characterized 
by low fibrinogen levels, which can produce 
hemorrhagic clinics, where anticoagulation 
can theoretically be dangerous in that 
condition [31].
Yale-New Haven Hospital (YNHH) and 
Massachusetts General Hospital (MGH) issued a local 
protocol of anticoagulation dosing guidelines including 
LMWH, heparin, fondaparinux, and DOAC (apixaban, 
rivaroxaban, and dabigatran) in prophylaxis and 
therapeutic management of VTE, as shown in Table 5.
Direct oral anticoagulant (DOAC)
Because of possible drug interactions between 
DOAC and combinations of antiviral (especially 
Figure 1: Algorithm of coagulopathy management in COVID-19 build on simple laboratory parameters. *The list of parameters is written in 
descending order of importance. **Taking a fibrinogen test may not be available in some laboratories, but monitoring levels can be helpful after 
hospitalization. ***Even though the specific cutoff cannot be defined, an increase in D-dimer 3-4-fold can be considered significant. One of the 
values in this table can be considered significant [23]
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anti-HIV protease inhibitors such as ritonavir) and 
antibacterial (such as azithromycin), LMWH or UFH 
should be preferred over DOAC. Such antiviral and 
antibacterial therapy interferes with the CYP3A4 and/or 
P-GP pathways, which can increase the risk of bleeding 
or reduce the antithrombotic effect in the case of DOAC 
use [19].
Fibrinolytic
At present, there are not enough data 
suggesting the use of more advanced therapies such 
as tissue plasminogen activator/tPA or to increase the 
dose of prophylactic anticoagulation in VTE associated 
with critically ill COVID-19 patients. There is evidence 
in animals and humans that fibrinolytic in acute 
lung injury and acute respiratory distress syndrome 
(ARDS) improves survival. This evidence also shows 
fibrin deposition in pulmonary microvasculature as 
the main cause of ARDS and is expected to be found 
in ARDS patients and a concurrent diagnosis of DIC 
seen in laboratory parameters, as observed in more 
than 70% of patients who died from COVID-19 [35]. 
Wang et al. reported three cases of intravenous tPA 
off-label (Alteplase) in COVID-19 patients with ARDS 
and respiratory failure. In all cases, patients showed 
an initial increase in the P/F ratio. However, the 
observed increase was temporary and disappeared 
over time in all three patients after completing their 
tPA infusion. They also mentioned that larger bolus 
tPA doses (50 mg or 100 mg bolus) without retaining 
anticoagulants are worth further considering and 
research to prevent the recurrence of suspected 
thrombosis of pulmonary microvascular that underlies 
ARDS in COVID-19 [35].
In conclusion, it is reasonable to give 
anticoagulant for prophylaxis treatment to all admitted 
patient with COVID-19. Heparin is the preferred 
anticoagulant for patients with COVID-19 because of its 
anti-inflammation property. Therapeutic anticoagulant 
should be given to patient with confirmed VTE or has 
high suspicion of developing VTE. The decision to 
give anticoagulation should be judged on patient-by-
patient basis, considering both risks of thrombosis and 
hemorrhage.
Is D-dimer above ~1,000-2,000 ng/mL?
Contraindicaon to ancoagulaon?
VTE prophylacc ancoagulaon (consider 
higher dose than standard dose, if D-Dimer is 
moderately elevated)
Follow serial D-Dimer (if D-Dimer rises above 
1,000-2,0000 ng/mL, then reconsider 
ancoagulaon)
Check fibrinogen level and/or TEG
Therapeuc ancoagulaon, e.g.:
- Normal renal funcon: therapeuc dose LMWH
- Renal failure: UFH infusion
Normal or hypercoagulable paern (nearly always)
- R-me low or normal on TEG
- Fibrinogen level is normal or elevated
Hypercoagulable paern (rare, late-stage)
- R-me prolonged on TEG
- Fibrinogen level is low
No ancoagulaon
- Follow fibrinogen level and/or TEG occasionally. Disconnue if 
ecidence of hypocagulable paern
- For severe hypercoagulability, consider addion of aspirin
Yes
No
Yes
No
Figure 2: Possible approach to empiric anticoagulation in COVID-19 (adapted from Farkas, 2020) [31]. LMWH: Low molecular weight heparin, 
TEG: Thromboelastography, UFH: Unfractionated heparin.
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Prognosis
Several studies proved the role of increased 
D-dimers as a predictor of mortality. Higher levels of 
D-dimer and fibrin degradation products showed to 
have associated with multi-organ dysfunction syndrome 
and worse prognosis [4], [7]. Huang et al. showed that 
the level of D-dimer at admission was higher in patients 
who needed critical care support (median [range] 
D-dimer level 2400 ng/mL [600–14.400]) compared to 
patients who did not need it (median [range] ] D-dimer 
level 0.5 ng/mL [300–800], p=0.0042) [29]. Tang et al. 
reported DIC development on the 4th day in 71.4% 
of patients who did not survive compared to only 
one patient (0.6%) who survived. They also reported 
increased D-dimer and PT levels with decreased levels 
of fibrinogen in those who did not survive on 10th and 
14th days significantly [7].
Sepsis patients are more likely to develop 
multi-organ failure in the presence of coagulopathy. 
Giving these patients medication which inhibits thrombin 
formation will likely aid in reducing mortality [23]. Study 
by Tang et al. proposed that monitoring D-dimers, PT, 
fibrinogen, and platelet counts can help to determine 
prognosis in patients with COVID-19. Aggressive critical 
care support is proposed if these parameters worsen.
Thrombocytopenia at presentation is 
considered to be a prognostic factor for mortality (OR, 
5.1; 95% CI, 1.8–14.6), as stated by Lippi et al. [34]. 
Thus, this study suggests the clinician provide adequate 
blood product and consider giving more “experimental’ 
therapies” as the data regarding therapies in COVID-19 
are still limited [7], [23].
Conclusion
Patients suffering from COVID-19 are at high 
risk of developing thrombosis, including VTE. Excessive 
inflammation, hypoxia, immobilization, aPL antibody, 
and diffuse intravascular coagulation contributes to 
development of VTE. There has been upcoming evidence 
regarding the presence of thrombosis in patients with 
severe COVID-19 infection. Prophylaxis anticoagulant 
Table 5: Prophylactic and therapeutic dosing of anticoagulation in VTE management
D-dimer Brigham and Women’s Hospital (BWH) Yale-New Haven Hospital (YNHH) Massachusetts General Hospital (MGH)
<500 ng/mL:
Prophylactic dose
GFR > 30 ml/min: 
Enoxaparin 40 mg SC q24h
GFR < 30 ml/min: 
UFH 5000 units SC q8h
BMI < 40 kg/m2
GFR ≥ 30: 
Enoxaparin 40 mg SC q24h
GFR < 30:
Enoxaparin 30 mg SC q24h
UFH 5000 units SC q12h
BMI ≥ 40 kg/m2
GFR ≥ 30: 
Enoxaparin 40 mg SC q12h 
GFR < 30:
Enoxaparin 40 mg SC q24h
Heparin 7500 units SC q12h
Standard dose
UFH: 5000 units SC q12h
Enoxaparin: 40 mg SC q24h
Fondaparinux: 2.5 mg SC q24h
Apixaban: 2.5 mg PO q12h
Rivaroxaban: 10 mg PO q24h
Dabigatran: 110 mg followed by 220 mg 
q24h
BMI ≥ 40 kg/m2
UFH: 5000 units SC q8h
Enoxaparin:
GFR ≥ 30: 40 mg SC q12h
GFR < 30: 40 mg SC q24h
≥500 ng/mL:
Intermediate 
prophylactic dose 
Recommended higher prophylactic  
dose by Klok et al. and Farkas.
GFR > 30 ml/min: 
Enoxaparin 0.5 mg/kg q12h.  Check an Xa level 
four hours after the third dose, targeting a level 
of ~0.5–0.8 IU/ml.
GFR < 30 ml/min: 
UFH 7,500 units q8hr (consider dose adjustment 
for atypical weight patients).
BMI < 40 kg/m2
GFR ≥ 30: 
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
GFR < 30:
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
UFH 7500 units SC q12h
BMI ≥ 40 kg/m2
GFR ≥ 30: 
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
GFR < 30:
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
UFH 7500 units SC q12h
Apixaban: 5 mg PO q12h regardless of renal function
n/a
Confirmed VTE 
or high clinical 
suspicion:
Therapeutic dose
n/a BMI < 40 kg/m2
GFR ≥ 30: 
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
GFR < 30:
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
Therapeutic UFH
BMI ≥ 40 kg/m2
GFR ≥ 30: 
Enoxaparin 0,5 mg/kg SC q12h
Apixaban 
GFR < 30:
Enoxaparin 1 mg/kg SC q24h
Apixaban 
Therapeutic UFH
Apixaban: 10 mg PO q12h × 7 days followed by 5 mg PO q12h
Standard dose:
UFH: 80 unit/kg bolus + 18 units/kg/hr 
infusion 
Enoxaparin: 1 mg/kg SC q12h
Fondaparinux: 
<50 kg: 5 mg SC q24h 
50–100 kg: 7.5 mg 124h
>100 kg: 10 mg q24h
BMI ≥ 40 kg/m2
Enoxaparin:
GFR ≥ 30: 0.75 mg/kg q12h
GFR < 30: 0.75 mg/kg q24h
n/a: Not available, BMI: Body mass index, GFR: Glomerular filtration rate, SC: Subcutaneously, UFH: Unfractionated heparin, VTE: Venous thromboembolism
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was proposed for all hospitalized COVID-19 patients. 
However, until additional data are available, when 
to initiate full therapeutic anticoagulation will remain 
controversial. For now, these decisions may be judged 
on a patient-by-patient basis, considering both risks of 
thrombosis and hemorrhage. Anti-inflammatory effect 
of LMWH may provide additional benefit in COVID-19 
patients.
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